Analgesics
Antiandrogens
Antihistamines
Azvudine
Bromhexine
Budesonide
Colchicine
Conv. Plasma
Curcumin
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Ivermectin
Lifestyle
Melatonin
Metformin
Minerals
Molnupiravir
Monoclonals
Naso/orophar..
Nigella Sativa
Nitazoxanide
Paxlovid
Quercetin
Remdesivir
Thermotherapy
Vitamins
More

Other
Feedback
Home
Top
Results
Abstract
All tixagevimab/cilgavimab..
Meta analysis
 
Feedback
Home
next
study
previous
study
c19early.org COVID-19 treatment researchTixagevimab/cilgavimabTixagev../c.. (more..)
Melatonin Meta
Metformin Meta
Antihistamines Meta
Azvudine Meta Molnupiravir Meta
Bromhexine Meta
Budesonide Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Paxlovid Meta
Famotidine Meta Quercetin Meta
Favipiravir Meta Remdesivir Meta
Fluvoxamine Meta Thermotherapy Meta
Hydroxychlor.. Meta
Ivermectin Meta

All Studies   Meta Analysis    Recent:   

Tixagevimab and Cilgavimab (Evusheld) as Pre-exposure Prophylaxis for COVID-19 in Patients With Inflammatory Bowel Disease: A Propensity Matched Cohort Study

Desai et al., Crohn's & Colitis 360, doi:10.1093/crocol/otad047
Sep 2023  
  Post
  Facebook
Share
  Source   PDF   All Studies   Meta AnalysisMeta
Hospitalization 12% Improvement Relative Risk Case -35% Tixagevimab/c..  Desai et al.  Prophylaxis Is prophylaxis with tixagevimab/cilgavimab beneficial for COVID-19? Retrospective 782 patients in the USA (January - October 2022) More cases with tixagevimab/cilgavimab (not stat. sig., p=0.18) c19early.org Desai et al., Crohn's & Colitis 360, Sep 2023 Favorstixagevimab/ci.. Favorscontrol 0 0.5 1 1.5 2+
39th treatment shown to reduce risk in May 2022
 
*, now with p = 0.000029 from 17 studies, recognized in 31 countries. Efficacy is variant dependent.
Lower risk for mortality, hospitalization, and cases.
No treatment is 100% effective. Protocols combine treatments. * >10% efficacy, ≥3 studies.
4,400+ studies for 79 treatments. c19early.org
TriNetX PSM retrospective 408 IBD patients receiving tixagevimab/cilgavimab and matched controls, showing no significant difference in COVID-19 cases or hospitalization.
Efficacy is variant dependent. In Vitro research suggests a lack of efficacy for omicron BA.2.75.2, BA.4.6, BQ.1.11, BA.5, BA.2.75, XBB2, ХВВ.1.9.1, XBB.1.9.3, XBB.1.5.24, XBB.1.16, XBB.2.9, BQ.1.1.45, CL.1, and CH.1.13.
risk of hospitalization, 12.0% lower, OR 0.88, p = 0.81, treatment 391, control 391, RR approximated with OR.
risk of case, 35.0% higher, OR 1.35, p = 0.18, treatment 391, control 391, RR approximated with OR.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Desai et al., 6 Sep 2023, retrospective, USA, peer-reviewed, 4 authors, study period 1 January, 2022 - 28 October, 2022.
This PaperTixagev../c..All
Tixagevimab and Cilgavimab (Evusheld) as Pre-exposure Prophylaxis for COVID-19 in Patients With Inflammatory Bowel Disease: A Propensity Matched Cohort Study
MD, * Aakash Desai, MD, MSc Jana G Hashash, MD Gursimran S Kochhar, MD, MSc Francis A Farraye
Crohn's & Colitis 360, doi:10.1093/crocol/otad047
Background: Tixagevimab and cilgavimab (Evusheld) are 2 fully human monoclonal antibodies that received emergency-use authorization on December 21, 2021, for pre-exposure prophylaxis of coronavirus disease 2019 (COVID-19) in patients who are moderate-severely immunocompromised. The real-world efficacy of Evusheld in patients with inflammatory bowel disease (IBD) is not known. Methods: We conducted a retrospective cohort study using TriNetX, a multi-institutional database in patients with IBD who received Evusheld compared to patients with IBD who did not receive Evusheld (12.1.2021-10.28.2022). The primary outcome was to assess the risk of COVID-19 within 6 months. One-to-one propensity score matching (PSM) was performed for demographic parameters, comorbid conditions, IBD medications, and history of COVID-19. Risk was expressed as adjusted odds ratio (aOR) with 95% confidence interval (CI). Results: Four hundred and eight patients (0.19%) with IBD received Evusheld (mean age 58.6 ± 15.4 years old, female 47.7%) during the study period. After PSM, there was no difference in the risk (aOR 0.88, 95% CI, 0.33-2.35) of COVID-19 in the Evusheld cohort compared to the IBD control cohort. No patients required ICU care or intubation/respiratory support or were deceased in the Evusheld cohort. Conclusions: Our study did not show that Evusheld decreases the risk of COVID-19 in patients with IBD. Prevention of moderate-severe COVID-19 in these patients should focus on vaccination strategies and early COVID-19 therapies.
Author Contributions A.D.: Data collection, data analysis and preparation of manuscript. J.G.H. and G.S.K.: Data interpretation and critical revision of the manuscript. F.A.F.: Study conceptualization, data interpretation, critical revision, and final approval of the manuscript. Conflicts of Interest A.D.: None exists. J.G.H. holds the position of Associate Editor for Crohn's & Colitis 360 and has been recused from reviewing or making decisions for the manuscript. G.S.K.: Advisor Board: Corvetas Research Foundation, Lilly Pharmaceuticals, GIE medical; Stock options: Digbi Health. F.A.F. is a consultant for BMS, Braintree Labs, GSK, IBD Educational Group, Innovation Pharmaceuticals, Janssen, Pfizer and Sebela. He sits on a DSMB for Adiso Therapeutics and Lilly.
References
Aqeel, Geetha, Tixagevimab and cilgavimab (Evusheld) in rituximab-treated antineutrophil cytoplasmic antibody vasculitis patients, Kidney Int Rep, doi:10.1016/j.ekir.2022.08.019
Coronavirus, COVID-19) update: FDA authorizes new long-acting monoclonal antibodies for pre-exposure prevention of COVID-19 in certain individuals, FDA. Published
Desai, Deepak, Cross, Effect of 2 vs 3 doses of COVID-19 vaccine in patients with inflammatory bowel disease: a population-based propensity matched analysis, Inflamm Bowel Dis, doi:10.1093/ibd/izac252
Focosi, Casadevall, A critical analysis of the use of cilgavimab plus tixagevimab monoclonal antibody cocktail (Evusheld TM ) for COVID-19 prophylaxis and treatment, Viruses, doi:10.3390/v14091999
Gungor, Kurtin, Mathias, Tanriover, Zangeneh, The prevention of COVID-19 in high-risk patients using tixagevimab-cilgavimab (Evusheld): Real-world experience at a large academic center, Am J Med, doi:10.1016/j.amjmed.2022.08.019
Hashah, Desai, Kochhar, Farraye, Efficacy of Paxlovid and Lagevrio for COVID-19 infection in patients with inflammatory bowel disease: a propensity-matched study, Clin Gastroenterol Hepatol, doi:10.1016/j.cgh.2022.09.011
Hutfless, Jasper, Tilak, A systematic review of Crohn's disease case definitions in administrative or claims databases, Inflamm Bowel Dis, doi:10.1093/ibd/izac131
Jurdi, Morena, Cote, Bethea, Azzi et al., Tixagevimab/cilgavimab pre-exposure prophylaxis is associated with lower breakthrough infection risk in vaccinated solid organ transplant recipients during the omicron wave, Am J Transplant, doi:10.1111/ajt.17128
Levin, Ustianowski, Wit, Intramuscular AZD7442 (tixagevimab-cilgavimab) for prevention of COVID-19, N Engl J Med, doi:10.1056/nejmoa2116620
Loo, Mctamney, Arends, The SARS-CoV-2 monoclonal antibody combination, AZD7442, is protective in nonhuman primates and has an extended half-life in humans, Sci Transl Med, doi:10.1126/scitranslmed.abl8124
Nguyen, Flahault, Chavarot, Pre-exposure prophylaxis with tixagevimab and cilgavimab (Evusheld©) for COVID-19 among 1112 severely immunocompromised patients, Clin Microbiol Infect, doi:10.1016/j.cmi.2022.07.015
Ocon, Mustafa, Real-world experience of tixagevimab and cilgavimab (Evusheld) in rheumatologic patients on rituximab, J Clin Rheumatol, doi:10.1097/rhu.0000000000001907
{ 'indexed': {'date-parts': [[2024, 2, 13]], 'date-time': '2024-02-13T17:26:03Z', 'timestamp': 1707845163613}, 'reference-count': 13, 'publisher': 'Oxford University Press (OUP)', 'issue': '3', 'license': [ { 'start': { 'date-parts': [[2023, 9, 6]], 'date-time': '2023-09-06T00:00:00Z', 'timestamp': 1693958400000}, 'content-version': 'vor', 'delay-in-days': 67, 'URL': 'https://creativecommons.org/licenses/by/4.0/'}], 'content-domain': {'domain': [], 'crossmark-restriction': False}, 'published-print': {'date-parts': [[2023, 7, 1]]}, 'abstract': '<jats:title>Abstract</jats:title>\n' ' <jats:sec>\n' ' <jats:title>Background</jats:title>\n' ' <jats:p>Tixagevimab and cilgavimab (Evusheld) are 2 fully human monoclonal ' 'antibodies that received emergency-use authorization on December 21, 2021, for pre-exposure ' 'prophylaxis of coronavirus disease 2019 (COVID-19) in patients who are moderate–severely ' 'immunocompromised. The real-world efficacy of Evusheld in patients with inflammatory bowel ' 'disease (IBD) is not known.</jats:p>\n' ' </jats:sec>\n' ' <jats:sec>\n' ' <jats:title>Methods</jats:title>\n' ' <jats:p>We conducted a retrospective cohort study using TriNetX, a ' 'multi-institutional database in patients with IBD who received Evusheld compared to patients ' 'with IBD who did not receive Evusheld (12.1.2021–10.28.2022). The primary outcome was to ' 'assess the risk of COVID-19 within 6 months. One-to-one propensity score matching (PSM) was ' 'performed for demographic parameters, comorbid conditions, IBD medications, and history of ' 'COVID-19. Risk was expressed as adjusted odds ratio (aOR) with 95% confidence interval ' '(CI).</jats:p>\n' ' </jats:sec>\n' ' <jats:sec>\n' ' <jats:title>Results</jats:title>\n' ' <jats:p>Four hundred and eight patients (0.19%) with IBD received Evusheld ' '(mean age 58.6 ± 15.4 years old, female 47.7%) during the study period. After PSM, there was ' 'no difference in the risk (aOR 0.88, 95% CI, 0.33–2.35) of COVID-19 in the Evusheld cohort ' 'compared to the IBD control cohort. No patients required ICU care or intubation/respiratory ' 'support or were deceased in the Evusheld cohort.</jats:p>\n' ' </jats:sec>\n' ' <jats:sec>\n' ' <jats:title>Conclusions</jats:title>\n' ' <jats:p>Our study did not show that Evusheld decreases the risk of COVID-19 ' 'in patients with IBD. Prevention of moderate–severe COVID-19 in these patients should focus ' 'on vaccination strategies and early COVID-19 therapies.</jats:p>\n' ' </jats:sec>', 'DOI': '10.1093/crocol/otad047', 'type': 'journal-article', 'created': {'date-parts': [[2023, 9, 6]], 'date-time': '2023-09-06T16:30:20Z', 'timestamp': 1694017820000}, 'source': 'Crossref', 'is-referenced-by-count': 1, 'title': 'Tixagevimab and Cilgavimab (Evusheld) as Pre-exposure Prophylaxis for COVID-19 in Patients With ' 'Inflammatory Bowel Disease: A Propensity Matched Cohort Study', 'prefix': '10.1093', 'volume': '5', 'author': [ { 'ORCID': 'http://orcid.org/0000-0002-6604-7712', 'authenticated-orcid': False, 'given': 'Aakash', 'family': 'Desai', 'sequence': 'first', 'affiliation': [ { 'name': 'Division of Gastroenterology and Hepatology, MetroHealth Medical ' 'Center, Case Western Reserve University , Cleveland, OH , USA'}]}, { 'ORCID': 'http://orcid.org/0000-0001-8305-9742', 'authenticated-orcid': False, 'given': 'Jana G', 'family': 'Hashash', 'sequence': 'additional', 'affiliation': [ { 'name': 'Division of Gastroenterology and Hepatology, Mayo Clinic , ' 'Jacksonville, FL , USA'}]}, { 'given': 'Gursimran S', 'family': 'Kochhar', 'sequence': 'additional', 'affiliation': [ { 'name': 'Division of Gastroenterology & Hepatology, Allegheny Health ' 'Network , Pittsburgh, PA , USA'}]}, { 'given': 'Francis A', 'family': 'Farraye', 'sequence': 'additional', 'affiliation': [ { 'name': 'Division of Gastroenterology and Hepatology, Mayo Clinic , ' 'Jacksonville, FL , USA'}]}], 'member': '286', 'published-online': {'date-parts': [[2023, 9, 6]]}, 'reference': [ { 'issue': '635', 'key': '2023090616205803500_CIT0001', 'doi-asserted-by': 'crossref', 'first-page': 'eabl8124', 'DOI': '10.1126/scitranslmed.abl8124', 'article-title': 'The SARS-CoV-2 monoclonal antibody combination, AZD7442, is protective ' 'in nonhuman primates and has an extended half-life in humans', 'volume': '14', 'author': 'Loo', 'year': '2022', 'journal-title': 'Sci Transl Med.'}, { 'issue': '23', 'key': '2023090616205803500_CIT0002', 'doi-asserted-by': 'crossref', 'first-page': '2188', 'DOI': '10.1056/NEJMoa2116620', 'article-title': 'Intramuscular AZD7442 (tixagevimab–cilgavimab) for prevention of ' 'COVID-19', 'volume': '386', 'author': 'Levin', 'year': '2022', 'journal-title': 'N Engl J Med.'}, {'key': '2023090616205803500_CIT0003'}, { 'issue': '12', 'key': '2023090616205803500_CIT0004', 'doi-asserted-by': 'crossref', 'first-page': '1654.e1', 'DOI': '10.1016/j.cmi.2022.07.015', 'article-title': 'Pre-exposure prophylaxis with tixagevimab and cilgavimab (Evusheld©) ' 'for COVID-19 among 1112 severely immunocompromised patients', 'volume': '28', 'author': 'Nguyen', 'year': '2022', 'journal-title': 'Clin Microbiol Infect'}, { 'issue': '1', 'key': '2023090616205803500_CIT0005', 'doi-asserted-by': 'crossref', 'first-page': '96', 'DOI': '10.1016/j.amjmed.2022.08.019', 'article-title': 'The prevention of COVID-19 in high-risk patients using ' 'tixagevimab–cilgavimab (Evusheld): Real-world experience at a large ' 'academic center', 'volume': '136', 'author': 'Al-Obaidi', 'year': '2022', 'journal-title': 'Am J Med.'}, { 'issue': '5', 'key': '2023090616205803500_CIT0006', 'doi-asserted-by': 'crossref', 'first-page': '705', 'DOI': '10.1093/ibd/izac131', 'article-title': 'A systematic review of Crohn’s disease case definitions in ' 'administrative or claims databases', 'volume': '29', 'author': 'Hutfless', 'year': '022', 'journal-title': 'Inflamm Bowel Dis.'}, { 'key': '2023090616205803500_CIT0007', 'doi-asserted-by': 'crossref', 'first-page': 'izac252', 'DOI': '10.1093/ibd/izac252', 'article-title': 'Effect of 2 vs 3 doses of COVID-19 vaccine in patients with ' 'inflammatory bowel disease: a population-based propensity matched ' 'analysis', 'author': 'Desai', 'year': '2022', 'journal-title': 'Inflamm Bowel Dis.'}, { 'issue': '9', 'key': '2023090616205803500_CIT0008', 'doi-asserted-by': 'crossref', 'first-page': '1999', 'DOI': '10.3390/v14091999', 'article-title': 'A critical analysis of the use of cilgavimab plus tixagevimab ' 'monoclonal antibody cocktail (EvusheldTM) for COVID-19 prophylaxis and ' 'treatment', 'volume': '14', 'author': 'Focosi', 'year': '2022', 'journal-title': 'Viruses'}, { 'issue': '2', 'key': '2023090616205803500_CIT0009', 'doi-asserted-by': 'crossref', 'first-page': '109', 'DOI': '10.1097/RHU.0000000000001907', 'article-title': 'Real-world experience of tixagevimab and cilgavimab (Evusheld) in ' 'rheumatologic patients on rituximab', 'volume': '29', 'author': 'Ocon', 'year': '2022', 'journal-title': 'J Clin Rheumatol'}, { 'issue': '11', 'key': '2023090616205803500_CIT0010', 'doi-asserted-by': 'crossref', 'first-page': '2537', 'DOI': '10.1016/j.ekir.2022.08.019', 'article-title': 'Tixagevimab and cilgavimab (Evusheld) in rituximab-treated ' 'antineutrophil cytoplasmic antibody vasculitis patients', 'volume': '7', 'author': 'Aqeel', 'year': '2022', 'journal-title': 'Kidney Int Rep'}, { 'issue': '12', 'key': '2023090616205803500_CIT0011', 'doi-asserted-by': 'crossref', 'first-page': '3130', 'DOI': '10.1111/ajt.17128', 'article-title': 'Tixagevimab/cilgavimab pre-exposure prophylaxis is associated with ' 'lower breakthrough infection risk in vaccinated solid organ transplant ' 'recipients during the omicron wave', 'volume': '22', 'author': 'Al Jurdi', 'year': '2022', 'journal-title': 'Am J Transplant.'}, { 'issue': '3', 'key': '2023090616205803500_CIT0012', 'article-title': 'Efficacy of Paxlovid and Lagevrio for COVID-19 infection in patients ' 'with inflammatory bowel disease: a propensity-matched study', 'volume': '21', 'author': 'Hashah', 'year': '2022', 'journal-title': 'Clin Gastroenterol Hepatol.'}, { 'key': '2023090616205803500_CIT0013', 'author': 'FDA announces Evusheld is not currently authorized for emergency use in the ' 'U.S', 'year': '2023'}], 'container-title': "Crohn's &amp; Colitis 360", 'original-title': [], 'language': 'en', 'link': [ { 'URL': 'https://academic.oup.com/crohnscolitis360/article-pdf/5/3/otad047/51393532/otad047.pdf', 'content-type': 'application/pdf', 'content-version': 'vor', 'intended-application': 'syndication'}, { 'URL': 'https://academic.oup.com/crohnscolitis360/article-pdf/5/3/otad047/51393532/otad047.pdf', 'content-type': 'unspecified', 'content-version': 'vor', 'intended-application': 'similarity-checking'}], 'deposited': { 'date-parts': [[2023, 9, 6]], 'date-time': '2023-09-06T16:30:27Z', 'timestamp': 1694017827000}, 'score': 1, 'resource': { 'primary': { 'URL': 'https://academic.oup.com/crohnscolitis360/article/doi/10.1093/crocol/otad047/7261634'}}, 'subtitle': [], 'short-title': [], 'issued': {'date-parts': [[2023, 7, 1]]}, 'references-count': 13, 'journal-issue': {'issue': '3', 'published-print': {'date-parts': [[2023, 7, 1]]}}, 'URL': 'http://dx.doi.org/10.1093/crocol/otad047', 'relation': {}, 'ISSN': ['2631-827X'], 'subject': ['Gastroenterology'], 'published-other': {'date-parts': [[2023, 7, 1]]}, 'published': {'date-parts': [[2023, 7, 1]]}}
Loading..
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit